164 related articles for article (PubMed ID: 27354582)
1. Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.
Johnson SD; Levingston C; Young MR
Anticancer Res; 2016 Jul; 36(7):3261-70. PubMed ID: 27354582
[TBL] [Abstract][Full Text] [Related]
2. Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.
Levingston CA; Young MR
Int J Cancer; 2017 Apr; 140(7):1609-1619. PubMed ID: 27914100
[TBL] [Abstract][Full Text] [Related]
3. Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.
Young MR; Levingston CA; Johnson SD
Int J Cancer; 2016 May; 138(10):2487-98. PubMed ID: 26756968
[TBL] [Abstract][Full Text] [Related]
4. Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer.
Young MR
J Immunother; 2008; 31(2):148-56. PubMed ID: 18481384
[TBL] [Abstract][Full Text] [Related]
5. Premalignant lesions skew spleen cell responses to immune modulation by adipocytes.
Vielma SA; Klein RL; Levingston CA; Young MR
Anticancer Res; 2013 May; 33(5):1809-18. PubMed ID: 23645725
[TBL] [Abstract][Full Text] [Related]
6. Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response.
De Costa AM; Justis DN; Schuyler CA; Young MR
Int Immunopharmacol; 2012 Jul; 13(3):322-30. PubMed ID: 22609090
[TBL] [Abstract][Full Text] [Related]
7. Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma.
Young MR; Neville BW; Chi AC; Lathers DM; Boyd Gillespie M; Day TA
Cancer Immunol Immunother; 2007 Jul; 56(7):1077-86. PubMed ID: 17096152
[TBL] [Abstract][Full Text] [Related]
8. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
9. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
10. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
Bergmann C; Strauss L; Zeidler R; Lang S; Whiteside TL
Cancer Res; 2007 Sep; 67(18):8865-73. PubMed ID: 17875728
[TBL] [Abstract][Full Text] [Related]
11. Production by human squamous cell carcinoma of a factor inducing activation and proliferation of immune cells.
Hirabayashi H; Yasumura S; Lin WC; Amoscato A; Johnson JT; Herberman RB; Whiteside TL
Arch Otolaryngol Head Neck Surg; 1995 Mar; 121(3):285-92. PubMed ID: 7873144
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.
De Costa AM; Schuyler CA; Walker DD; Young MR
Cancer Immunol Immunother; 2012 Jun; 61(6):927-39. PubMed ID: 22116344
[TBL] [Abstract][Full Text] [Related]
13. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer.
Heusinkveld M; Goedemans R; Briet RJ; Gelderblom H; Nortier JW; Gorter A; Smit VT; Langeveld AP; Jansen JC; van der Burg SH
Int J Cancer; 2012 Jul; 131(2):E74-85. PubMed ID: 22020783
[TBL] [Abstract][Full Text] [Related]
14. Cell surface markers for T and B lymphocytes activation and adhesion as putative prognostic biomarkers for head and neck squamous cell carcinoma.
Andrade MC; Ferreira SB; Gonçalves LC; De-Paula AM; de Faria ES; Teixeira-Carvalho A; Martins-Filho OA
Hum Immunol; 2013 Dec; 74(12):1563-74. PubMed ID: 23994583
[TBL] [Abstract][Full Text] [Related]
15. Tim-3-expressing macrophages are functionally suppressed and expanded in oral squamous cell carcinoma due to virus-induced Gal-9 expression.
Dong J; Cheng L; Zhao M; Pan X; Feng Z; Wang D
Tumour Biol; 2017 May; 39(5):1010428317701651. PubMed ID: 28466780
[TBL] [Abstract][Full Text] [Related]
16. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
18. Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.
Younis RH; Han KL; Webb TJ
J Immunol; 2016 Feb; 196(3):1419-29. PubMed ID: 26740106
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
[TBL] [Abstract][Full Text] [Related]
20. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
